Attovia Therapeutics, Inc.

424B4 priced

Price $17.00 · 17,000,000 shares · Gross proceeds $268,770,000

EFFECT effective

CERT inactive

S-1/A amended

Price $17.00 · 17,000,000 shares

Attovia Therapeutics, Inc. is an early-stage biopharmaceutical company focused on developing biotherapeutics for immune-mediated diseases, with no products approved for commercial sale and significant historical operating losses. The company is conducting clinical trials for product candidates ATTO-1310, ATTO-2306, and ATTO-1091, but has not yet demonstrated the ability to complete clinical trials, obtain regulatory approvals, or generate product revenue. The current S-1/A filing reflects adjustments to the IPO structure, including a 1-for-9.29 reverse stock split, revised pro forma financials, and updated share offerings, while highlighting ongoing risks related to capital requirements, clinical development, and regulatory uncertainties.

8-A12B effective

S-1/A amended

Price $16.00 · Range $15.00 to $17.00 · 12,500,000 shares · Gross proceeds $200,000,000

Attovia Therapeutics, Inc. is an early clinical-stage biopharmaceutical company focused on developing biotherapeutics for immune-mediated diseases. The company is undergoing an IPO, with the current S-1/A filing detailing the offering of shares, including 21,517,976 shares from the conversion of redeemable convertible preferred stock, a 1-for-9.29 reverse stock split, and a 410,000-share ESPP. The filing highlights significant financial losses, with a $129.7 million accumulated deficit as of March 31, 2026, and expects continued losses as it advances clinical trials for its product candidates. The offering includes pro forma adjustments for capital structure changes and potential stock price variations.

S-1 filed

Attovia Therapeutics, Inc. is conducting an IPO as outlined in its S-1 filing, detailing financials, risk factors, and capital structure adjustments. The company, an early-stage biopharmaceutical firm, has no approved products, significant operating losses, and relies on private equity financing. The filing includes adjustments to share counts, including preferred stock conversion to common stock and a reverse stock split, alongside pro forma financial data reflecting potential IPO outcomes.

DRS/A amended

DRS/A amended

DRS filed